Home News Updates on SpyGlass Platform for Glaucoma Treatment back to News
minute read
New 6-month results from a first-in-human trial investigating the SpyGlass drug delivery platform indicated continued reductions in intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
